A variant in PPP4R3A protects against alzheimer‐related metabolic decline
Abstract
A reduction in glucose metabolism in the posterior cingulate cortex (PCC) predicts conversion to Alzheimer's disease (AD) and tracks disease progression, signifying its importance in AD. We aimed to use decline in PCC glucose metabolism as a proxy for the development and progression of AD to discover common genetic variants associated with disease vulnerability.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2017
- Source ID
- 10.1002/ana.25094
Entities
People
- For The Alzheimer’s Disease Neuroimaging Initiative*
- Leigh Christopher
- Michael D. Greicius
- Raiyan R. Khan
- Summer S. Han
- Valerio Napolioni
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- Innogenetics
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Pfizer
- Roche (United States)
- Stanford University
- Takeda Pharmaceutical Company
- United States Department of Defense